Literature DB >> 32405122

COVID-19: Developing from an Outbreak to A Pandemic.

Sara Hanaei1, Nima Rezaei2.   

Abstract

Entities:  

Year:  2020        PMID: 32405122      PMCID: PMC7219390          DOI: 10.1016/j.arcmed.2020.04.021

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


× No keyword cloud information.
In late 2019, there were first reports of an outbreak of unknown-caused pneumonia from Wuhan, Hubei province, China. After a week of investigations, the novel coronavirus, COVID-19, was found as the etiologic factor (1). The virus was a mutated form of Coronaviridae family, which similar to many other respiratory viruses, was comprised of a RNA component covered by viral capsid protein, but acquired a novel genomic mutation, making it resistant to standard medications (2). Highly contagious with droplets and contact transmission, the virus might stay silent for a period of 2.4–15.5 d (3) and then manifests with flu-like symptoms, non-suppurative coughs, fever, diarrhea, myalgia, or even anosmia in some cases. The lungs will be the next victims and in severe cases, after a course of 1–2 weeks, the patients would die due to acute respiratory distress syndrome. Although primarily reported to be originated from a seafood market in China, it was later reported that human-to-human transmission would play the most crucial role in disease spread (4). It almost took 1.5 month that the outbreak was controlled in China, with a primary increasing trend, steep slope, and then the downtrend. This demonstrates not only the normal trend of an infectious outbreak, but also the role of human interventions to control it. Considering the crowded population of China, health-care preventive and therapeutic interventions were important in restricting the extent of outbreak, as if the natural history of outbreak would have been passed, much more affected patients and deaths were the result. Affecting over 100 patients China, the first reports in other regions came from Thailand, Japan, and South Korea, as the second line affected countries, in which all were infected through transmission from confirmed cases of COVID-19 from China (1). While struggling in the life-and-death battle of COVID-19 outbreak in China, the other countries, were almost in peace, until the second half of February. Interestingly, the beginning of uptrend in other countries was almost simultaneous with beginning of the downtrend in China. This can further be explained by the role of incubation period in estimating the true prevalence of this disease; as although many of the patients were affected in other countries, they were asymptomatic carriers in the incubation period, who could silently infect many others. Therefore, the steep slope of the curves was created when the fist incubation periods were finished. Moreover, some diagnostic biases could have led underdiagnoses of patients before. In other words, as the symptoms of COVID-19 were similar to other pneumonias, some of mild cases could have been clinically diagnosed with community acquired pneumonia without being tested for COVID-19 until late stages. On the other hands, severe cases, such as those with comorbidities, could cause bias in overestimating viral shedding time and severity of disease symptoms (5). Eventually, after infecting over 118,000 patients in over 100 countries, and causing more than 4200 deaths, the outbreak was called a “pandemic” by WHO on March 11th 2020 (6). As one of the neighboring countries of China, South Korea was one of the first countries to be affected by COVID-19. Considering the epidemic curve of South Korea, the outbreak was controlled in less than a month, which may demonstrate timely, efficient actions in prevention and control of this pandemic. Germany and USA could be representative of facing an outbreak in a developed country. Although the steep slope of both countries started later than some other high-prevalent ones, the reported new cases became quite high considering their population. This could be interpreted as the role of an efficient screening protocol for detecting the patients in mild stages. Also, despite the high frequency, the death rates were not as much high in them. This also demonstrates the efficiency of patient-management in controlling the pandemic. The first cases of COVID-19 in Italy were reported one month after China, which could be explained based on the incubation period and transmission rate of disease. Despite the disease-controlling actions such as isolation of infected cities, restricting transportations, and therapeutic approaches, they were not efficient enough to restrict the outbreak, and it developed to involve over a hundred thousand people and cause thousands of deaths. Although the first case of COVID-19 in Spain was reported in early February, there was a 2 week interval until beginning of the steep slope. Therefore, it could be learnt that in the time of an important pandemic, incidence of even one case shall be taken seriously. France was one of the top 10 countries reporting new cases of COVID-19. The pattern of its epidemic curve is similar to Germany in the matter of new cases. However, it is remarkably different in the matter of deaths, which may demonstrate the difference of these two countries in patient management. Although no infected cases of COVID-19 were reported from Iran until late February (7), the outbreak quickly raised with a short interval between first report and steep slope. This might be suggestive for misdiagnosis, and unavailability of adequate diagnostic facilities. Besides, inadequate preventive equipment, and transportation restriction could potentially be considered as a cause of increased incidence and death in Iran (Figure 1 ) (8).
Figure 1

Comparative graphs of daily patients (A) and deaths (B) in some high-prevalent counties. (Update: May 6th, 2020)

Comparative graphs of daily patients (A) and deaths (B) in some high-prevalent counties. (Update: May 6th, 2020) The world has encountered several pandemics in the past 2 centuries. Therefore, no matter to which cause, the outbreaks might be inevitable to occur sometimes; but, more important to be considered, is how we approach them to be defined and controlled. First, it should be taken to account that even though some countries, especially the developing ones, might not be marked on the leading board of affected countries, the probability of high prevalence shall not be ignored in them. This is important as low reports in such countries could be a result of inadequate diagnostic tests rather than low prevalence. Second, the approach to control a pandemic would make more sense in case of international collaborations in the matters of disease prevention and treatment. While preventive approaches such as restricting transportation or preventive equipment may be the first lines, research investigations for developing specific medication and vaccines come as the second line of encountering an outbreak.
  3 in total

1.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

Review 2.  MERS coronavirus: data gaps for laboratory preparedness.

Authors:  Rita de Sousa; Chantal Reusken; Marion Koopmans
Journal:  J Clin Virol       Date:  2013-11-07       Impact factor: 3.168

3.  Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020.

Authors:  Jantien A Backer; Don Klinkenberg; Jacco Wallinga
Journal:  Euro Surveill       Date:  2020-02
  3 in total
  31 in total

1.  Nutrition and Immunity in COVID-19.

Authors:  Marjan Moallemian Isfahani; Zahra Emam-Djomeh; Idupulapati M Rao; Nima Rezaei
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.

Authors:  Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei
Journal:  Eur J Pharmacol       Date:  2021-06-12       Impact factor: 4.432

3.  Cytokines and COVID-19: friends or foes?

Authors:  Mohsen Rokni; Michael R Hamblin; Nima Rezaei
Journal:  Hum Vaccin Immunother       Date:  2020-08-25       Impact factor: 3.452

4.  Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge.

Authors:  Nima Rezaei; Saboura Ashkevarian; Mahsa Keshavarz Fathi; Sara Hanaei; Zahra Kolahchi; Seyedeh-Sanam Ladi Seyedian; Elham Rayzan; Mojdeh Sarzaeim; Aida Vahed; Kawthar Mohamed; Sarah Momtazmanesh; Negar Moradian; Zahra Rahimi Pirkoohi; Noosha Sameeifar; Mahsa Yousefpour; Sepideh Sargoli; Saina Adiban; Aida Vahed; Niloufar Yazdanpanah; Heliya Ziaei; Amene Saghazadeh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Coronavirus: Pure Infectious Disease or Genetic Predisposition.

Authors:  Farzaneh Darbeheshti; Hassan Abolhassani; Mohammad Bashashati; Saeid Ghavami; Sepideh Shahkarami; Samaneh Zoghi; Sudhir Gupta; Jordan S Orange; Hans D Ochs; Nima Rezaei
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  COVID-19 in Patients with Cancer.

Authors:  Ali Nowroozi; Sepideh Razi; Kamal Kant Sahu; Fabio Grizzi; Jann Arends; Mahsa Keshavarz-Fathi; Nima Rezaei
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Cognitive Biases Affecting the Maintenance of COVID-19 Pandemic.

Authors:  Kawthar Mohamed; Niloufar Yazdanpanah; Amene Saghazadeh; Nima Rezaei
Journal:  Acta Biomed       Date:  2021-05-12

Review 8.  Biosensing surfaces and therapeutic biomaterials for the central nervous system in COVID-19.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  Emergent Mater       Date:  2021-03-10

9.  Emerging Standards and the Hybrid Model for Organizing Scientific Events During and After the COVID-19 Pandemic.

Authors:  Sara Hanaei; Amirhossein Takian; Reza Majdzadeh; Christopher Ryan Maboloc; Igor Grossmann; Orlando Gomes; Milos Milosevic; Manoj Gupta; Alireza A Shamshirsaz; Amine Harbi; Amer M Burhan; Lucina Q Uddin; Arutha Kulasinghe; Chi-Ming Lam; Seeram Ramakrishna; Abass Alavi; Jan L Nouwen; Tommaso Dorigo; Michael Schreiber; Ajith Abraham; Natalya Shelkovaya; Wojtek Krysztofiak; Majid Ebrahimi Warkiani; Frank Sellke; Shuji Ogino; Francisco J Barba; Serge Brand; Clara Vasconcelos; Deepak B Salunke; Nima Rezaei
Journal:  Disaster Med Public Health Prep       Date:  2020-10-26       Impact factor: 1.385

10.  Predictors of compliance with COVID-19 related non-pharmaceutical interventions among university students in the United States.

Authors:  Spencer G Shumway; Jonas D Hopper; Ethan R Tolman; Daniel G Ferguson; Gabriella Hubble; David Patterson; Jamie L Jensen
Journal:  PLoS One       Date:  2021-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.